MedSuN surveillance programme to include blood centres
This article was originally published in Clinica
Executive Summary
Blood and transfusion centres will be included in the US FDA's upcoming pilot programme of a new adverse event reporting scheme, the Medical Product Surveillance Network or MedSuN, according to agency documents made available last week.